Andrew J. Armstrong

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

  European Journal of Cancer · 2023 · https://doi.org/10.1016/j.ejca.2023.02.018

• Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · 10.1016/s1470-2045(23)00382-0

• Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200043

• Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.00193

• NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

  Journal of the National Comprehensive Cancer Network · 2021 · https://doi.org/10.6004/jnccn.2021.0008

• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00799

• Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2019 · https://doi.org/10.6004/jnccn.2019.0023

• Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.01731

• A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-1912

• Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

  Pharmacology & Therapeutics · 2018 · https://doi.org/10.1016/j.pharmthera.2018.09.007

• Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00515-x

• Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.9285

• Prostate Cancer, Version 1.2016

  Journal of the National Comprehensive Cancer Network · 2016 · https://doi.org/10.6004/jnccn.2016.0004

• Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.65.7270

• Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

  European Urology · 2016 · https://doi.org/10.1016/j.eururo.2016.07.032

• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.2702

• Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity

  European Urology · 2014 · https://doi.org/10.1016/j.eururo.2014.04.029

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1405095

• Prostate Cancer, Version 2.2014

  Journal of the National Comprehensive Cancer Network · 2014 · 10.6004/jnccn.2014.0072

• Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70479-0

• Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt138

• Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

  Endocrine Related Cancer · 2013 · 10.1530/erc-12-0394

• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1207506

• Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

  Molecular Cancer Research · 2011 · https://doi.org/10.1158/1541-7786.mcr-10-0490

• Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

  European Urology · 2011 · https://doi.org/10.1016/j.eururo.2011.11.009

• A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

  Clinical Cancer Research · 2007 · https://doi.org/10.1158/1078-0432.ccr-07-1036

• Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.4769

Current projects

No projects listed.